Equity research

Analysts

Firm Analyst
Aurgalys Jean-Pierre Loza - jp.loza@aurgalys.com
Edison Maxim Jacobs - mjacobs@edisongroup.com
Invest Securities Martial Descoutures - mdescoutures@invest-securities.com
Maxim Group Jason McCarthy, Ph.D. - jmccarthy@maximgrp.com
Quantum Genomics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Quantum Genomics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Quantum Genomics or its management. Quantum Genomics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

2018

Analyst report Edison – 2018/07/13 – A little company going after big indications pdf

Analyst report Edison – 2018/06/28 – The QUORUM trial pdf

Analyst report Aurgalys – 2018/04/24 – “BAPAIs Fast Growth”, Quantum Genomics strategy for the next three years pdf

Analyst report Edison – 2018/04/23 – Accelerating timelines pdf

Morning Invest Securities – 2018/04/23 – Accelerating clinical developments (french only) pdf

Analyst report Aurgalys – 2018/04/09 – 2017, an intensification of clinical activity with NEW-HOPE and QUID HF pdf

Analyst report Edison – 2018/04/04 – NEW-HOPE trial recruiting rapidly pdf

Analyst report Aurgalys – 2018/02/16 – Aurgalys is contracted by Quantum Genomics to provide equity research pdf

2017

Analyst report Aurgalys – 2017/10/25 – Quantum Genomics published its H-1 2017 financial results and launched the NEW-HOPE study in the United States pdf

Analyst report Edison – 2017/10/05 – NEW-HOPE trial launched pdf

Analyst report Invest Securities – 2017/07/27 – Strong upside at the price of a high dilution (french only) pdf

Analyst report Edison – 2017/06/27 – QGC001 clinical results pdf

Analyst report Aurgalys – 2017/06/20 – A decisive phase II in the US to validate QGC001’s efficacy pdf

Morning Invest Securities – 2017/06/19 – Signs of Efficacy on Patients With High HBP (french only) pdf

Analyst report Edison – 2017/04/04 – Accelerating clinical studies pdf

Invest Securities flash – 2017/04/03 – 2016 annual results (french only)  pdf

Analyst report Aurgalys – 2017/02/17 – Quantum Genomics strengthens IP on BAPAIs while preparing the US phase 2 trial in hypertension pdf

Invest Securities Biotech Review – 2017/01/26 – Quantum Genomics, top pick H1 2017 pdf

 

2016

Initiation of coverage Edison – 2016/11/28 – Quantum Genomics : The next generation of cardiac drugs  pdf

Invest Securities flash – 2016/10/11 – A first step well underway (french only)  pdf

Analyst report Aurgalys – 2016/10/05 – Quantum Genomics establishes first clinical proof of efficacy of QGC001 in hypertension pdf

Invest Securities flash – 2016/07/04 – QGC001 attendu en septembre (french only)  pdf

Analyst report Aurgalys – 2016/05/24 – Extended US patent protection for Quantum Genomics’ drug candidates pdf

Analyst report Aurgalys – 2016/04/04 – Quantum Genomics raises €8.6M to fund Phase II clinical programs in hypertension and heart failure pdf

Invest Securities flash – 2016/03/29 – Sécuriser pour mieux avancer (french only)  pdf

Analyst report Aurgalys – 2016/01/06 – 2016, a decisive year for Quantum Genomics pdf

 

2015

Analyst report Aurgalys – 2015/10/12 – Quantum Genomics gets first positive DSMB with QGC001 in hypertension pdf

Aurgalys analyst report – 2015/07/08 – Quantum Genomics accelerates clinical development of QGC101 in Congestive Heart Failure  Read more

Invest Securities flash – 2015/06/30 – Positive results in the dog (french only)  Read more

Invest Securities equity research – 2015/05/28 – Initiation of coverage: “APA”for the bigpharmas?  Read more

Aurgalys equity research – 2015/02/25 – €12.9M in Equity Financing: Quantum Genomics makes investor’s hearts beat  Read more

Invest Securities equity research – 2015/01/27   Read more

2014

Aurgalys equity research – 2014/11/04 – Quantum Genomics could revolutionize the hypertension market  Read more